Allogene ditches enhanced lymphodepletion
The move comes after a death in the Alpha-3 cema-cel study.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Columvi avoids its worst-case scenario
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
Bristol seeks another celmod use
Golcadomide will begin a new pivotal trial in follicular lymphoma.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
